Trading With A Small Account?

From Tradewins | Ad

If you’ve been told it’s not doable, you’ve been lied to! Hi, I’m pro-trader Chuck Hughes and I grew my once tiny investment into an empire!

If you want to do the same–or simply want to feel more secure in your finances–”Options Trading Made Easy” is the guide you need.

Get a copy here!

>>>

Seth H.Z. Fischer, insider at Spectrum Pharmaceuticals

Seth H.Z. Fischer Insider Information

Director of Spectrum Pharmaceuticals

Mr. Fischer currently serves as a member of the Board of Directors of Marinus Pharmaceuticals, Inc. (MRNS), Agile Therapeutics, Inc. (AGRX), and is also an advisor to MedHab, LLC. Previously, Mr. Fischer served as the Chief Executive Officer and as a Director of Vivus, Inc., a publicly traded biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health from September 2013 to December 2017.

Prior to Vivus, Mr. Fischer served in various positions of increasing responsibility at Johnson & Johnson, most recently as company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Prior to that, he served as company Group Chairman, North America Pharmaceuticals, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals. Mr. Fischer’s operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including neurologic products for epilepsy and migraines and products in the analgesic, anti-infective, cardiovascular, psychiatric and women’s health areas. From May 2013 to May 2019, Mr. Fischer also served on the Board of Directors of BioSig Technologies, Inc.

Mr. Fischer brings to the Board over 37 years of experience in the pharmaceutical industry, including 29 years in various leadership roles at Johnson & Johnson.

What is Seth H.Z. Fischer's net worth?: The estimated net worth of Seth H.Z. Fischer is at least $22,671.48 as of June 21st, 2022. Mr. Fischer owns 29,066 shares of Spectrum Pharmaceuticals stock worth more than $22,671 as of July 1st. This net worth evaluation does not reflect any other investments that Mr. Fischer may own. Learn More about Seth H.Z. Fischer's net worth.
How do I contact Seth H.Z. Fischer?: The corporate mailing address for Mr. Fischer and other Spectrum Pharmaceuticals executives is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. Spectrum Pharmaceuticals can also be reached via phone at (702) 835-6300 and via email at [email protected] Learn More on Seth H.Z. Fischer's contact information.
Has Seth H.Z. Fischer been buying or selling shares of Spectrum Pharmaceuticals?: Seth H.Z. Fischer has not been actively trading shares of Spectrum Pharmaceuticals within the last three months. 0 shares of BMO Capital Markets stock in a transaction that occurred on Friday, July 1st. Learn More on Seth H.Z. Fischer's trading history.
Who are Spectrum Pharmaceuticals' active insiders?: Spectrum Pharmaceuticals' insider roster includes Seth Fischer (Director), Francois Lebel (Insider), Keith Mcgahan (Insider), and Thomas Riga (COO). Learn More on Spectrum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Spectrum Pharmaceuticals?: During the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 133,245 shares worth more than $106,605.01. The most recent insider tranaction occured on June, 22nd when insider Francois Lebel sold 6,096 shares worth more than $4,937.76. Insiders at Spectrum Pharmaceuticals own 2.7 % of the company. Learn More about insider trades at Spectrum Pharmaceuticals.
Information on this page was last updated on 6/22/2022.

Seth H.Z. Fischer Insider Trading History at Spectrum Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/21/2022	Sell	5,711	$0.79	$4,511.69	29,066
6/18/2021	Sell	12,000	$4.24	$50,880.00	46,777

Seth H.Z. Fischer Buying and Selling Activity at Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Company Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.

Today's Range

Now: $0.78

$0.77

$0.82

50 Day Range

MA: $0.81

$0.70

$1.00

2 Week Range

Now: $0.78

$0.60

$3.83

Volume

1,831,014 shs

Average Volume

3,594,850 shs

Market Capitalization

$140.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.24